Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus

被引：0

作者：

Farhan, Serdar ^{[1
]}

Hochtl, Thomas ^{[1
]}

Kautzky-Willer, Alexandra ^{[2
]}

Wojta, Johann ^{[3
]}

Huber, Kurt ^{[1
]}

机构：

[1] Wilhelminen Hosp, Dept Cardiol & Emergency Med 3, Montleatstr 37, A-1160 Vienna, Austria

[2] Univ Med, Dept Endocrinol & Metab 3, Vienna, Austria

[3] Univ Med Vienna, Dept Cardiol 2, Vienna, Austria

来源：

WIENER MEDIZINISCHE WOCHENSCHRIFT | 2010年 / 160卷 / 1-2期

关键词：

Coronary artery disease; acute coronary syndrome; diabetes mellitus;

D O I：

10.1007/s10354-010-0747-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diabetes mellitus (DM) is a life-threatening disease. Patients with DM have a 2- to 4-fold higher risk of developing cardiovascular disease compared to their non-diabetic counterparts. Several drugs are available for the treatment of stable coronary artery disease (CAD) and acute coronary syndrome (ACS). Among oral antiplatelet agents (acetylsalicylic acid, ticlopidine, clopidogrel, and prasugrel), prasugrel has shown the highest efficacy in patients with DM and ACS. The use of glycoprotein IIb-IIIa receptor inhibitors in diabetic subjects with ACS undergoing percutaneous coronary intervention (PCI) reduces adverse clinical events in a greater extent than in non-diabetics. Several direct and indirect antithrombins are recommended for the treatment of ACS such as unfractionated heparin (UFH), enoxaparin, fondaparinux, and bivalirudin. Enoxaparin and bivalirudin have been shown to be superior to UFH among patients with ST-elevation MI (STEMI) and non-ST elevation MI (NSTEMI) also in diabetic subgroup analyses.

引用

页码：30 / 38

页数：9

共 87 条

[1] Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial [J].

Alexander, John H. ;

Becker, Richard C. ;

Bhatt, Deepak L. ;

Cools, Frank ;

Crea, Filippo ;

Dellborg, Mikael ;

Fox, Keith A. A. ;

Goodman, Shaun G. ;

Harrington, Robert A. ;

Huber, Kurt ;

Husted, Steen ;

Lewis, Basil S. ;

Lopez-Sendon, Jose ;

Mohan, Puneet ;

Montalescot, Gilles ;

Ruda, Mikhail ;

Ruzyllo, Witold ;

Verheugt, Freek ;

Wallentin, Lars ;

Darius, Harald ;

Simoons, Maarten ;

Boersma, Eric ;

DeLemos, James ;

Spencer, Fred .

CIRCULATION, 2009, 119 (22) :2877-U39

[2] Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin [J].

Algra, A ;

Van Gijn, J .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (02) :255-255

[3] Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease - Results of the Optimizing antiPlatelet Therapy In diabetes MellitUS (OPTIMUS) study [J].

Angiolillo, Dominick J. ;

Shoemaker, Steven B. ;

Desai, Bhaloo ;

Yuan, Hang ;

Charlton, Ronald K. ;

Bernardo, Esther ;

Zenni, Martin M. ;

Guzman, Luis A. ;

Bass, Theodore A. ;

Costa, Marco A. .

CIRCULATION, 2007, 115 (06) :708-716

[4]

Antman EM, 2008, J AM COLL CARDIOL, V51, P2028, DOI [10.1016/j.jacc.2008.04.002, 10.1016/j.jacc.2007.10.001]

[5] Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction [J].

Antman, EM ;

Morrow, DA ;

McCabe, CH ;

Murphy, SA ;

Ruda, M ;

Sadowski, Z ;

Budaj, A ;

López-Sendón, JL ;

Guneri, S ;

Jiang, F ;

White, HD ;

Fox, KAA ;

Braunwald, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (14) :1477-1488

[6] Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) [J].

Antman, EM ;

Morrow, DA ;

McCabe, CH ;

Jiang, F ;

White, HD ;

Fox, KAA ;

Sharma, D ;

Chew, P ;

Braunwald, E .

AMERICAN HEART JOURNAL, 2005, 149 (02) :217-226

[7] Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction - Results of the thrombolysis in myocardial infarction (TIMI) 11B trial [J].

Antman, EM ;

McCabe, CH ;

Gurfinkel, EP ;

Turpie, AGG ;

Bernink, PJLM ;

Salein, D ;

de Luna, AB ;

Fox, K ;

Lablanche, JM ;

Radley, D ;

Premmereur, J ;

Braunwald, E .

CIRCULATION, 1999, 100 (15) :1593-1601

[8] TISSUE-TYPE PLASMINOGEN-ACTIVATOR ANTIGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR IN DIABETES-MELLITUS [J].

AUWERX, J ;

BOUILLON, R ;

COLLEN, D ;

GEBOERS, J .

ARTERIOSCLEROSIS, 1988, 8 (01) :68-72

[9]

Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71

[10] Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction [J].

Baird, SH ;

Menown, IBA ;

McBride, SJ ;

Trouton, TG ;

Wilson, C .

EUROPEAN HEART JOURNAL, 2002, 23 (08) :627-632

← 1 2 3 4 5 6 7 8 9 →